GSK's Hal Barron On R&D Progress At Two-Year Mark
R&D Chief Says Doubters Are Coming Round
Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.
You may also be interested in...
Two new PARP inhibitor studies – GSK’s PRIMA and AstraZeneca/Merck & Co.’s PAOLA-1 – are set to widen the ovarian cancer market after they reported highly positive first-line results in advanced patients at ESMO.
Once a pariah because of its price gouging, the new approval represents a change of tack from Horizon.
Often dismissed as a meeting of the global elite, Davos is nevertheless a chance for biopharma leaders to take part in ‘big picture’ debates